Clinical Trials Directory

Trials / Completed

CompletedNCT04636411

Effects of Oral Magnesium Supplementation on Patients With Type 2 Diabetes

Evaluation of the Effects of Oral Magnesium Supplementation on Glycemic Control and Inflammation Among Patients With Type 2 Diabetes

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Samar Fares, MD · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A total of 74 Adult Patients with type 2 diabetes mellitus (T2D) will be enrolled and randomized into 2 groups. The intervention group will receive oral magnesium (Mg) supplementation. The study objectives are: 1. To estimate level of Mg (total and ionized) in patient with type 2 DM. 2. To determine the effect of Mg supplementation for diabetic patient on serum Mg level, glycemic control and level of inflammation. 3. To assess the correlation between serum Mg level and glycemic control and level of inflammatory mediators (CRP)

Detailed description

A total of 74 Adult Patients of both genders who had been diagnosed with T2D and are on oral anti-hyperglycemic drug and their HbA1C between 7and 8 %, will be enrolled in the study. Initially the study protocol will be explained \& informed written consent will be obtained from all participants. All subjects will be evaluated to ensure that they meet the eligibility criteria through: Full history taking, complete physical examination and investigations. the intervention group will receive oral magnesium (Mg) supplementation for 3 months (250 mg of elemental magnesium daily). The primary outcome is to determine the effect of Mg supplementation for diabetic patient on serum Mg level, glycemic control and level of inflammation.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTOral Magnesium Supplementation250 mg of elemental magnesium daily for three months
OTHERStandard Care for diabetic patientsHealth education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines

Timeline

Start date
2020-11-01
Primary completion
2021-10-31
Completion
2021-12-31
First posted
2020-11-19
Last updated
2024-02-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04636411. Inclusion in this directory is not an endorsement.